Kite Pharma, Inc. - Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma
Partner
Not provided
Rare Disease
Relapsed/Refractory Transplant Ineligible Primary Mediastinal B Cell Lymphoma
Sponsor
Kite Pharma, Inc.
Access Program Information
This is a multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory transplant ineligible aggressive NHL.
Contact
Contact: Medical Information (844-454-KITE)
Locations
- United States
- Stanford, California, United States
- United States
- Tampa, Florida, United States
- United States
- Chicago, Illinois, United States
- United States
- Boston, Massachusetts, United States
- United States
- Houston, Texas, United States